Creatine Cognition Randomized Trial: What the Evidence Says

Quick Answer

Creatine Cognition Randomized Trial has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are systematic review, randomized trial, so conclusions should be framed as evidence-aware guidance rather than medical advice.

Key Takeaways

• This page is generated only from sources stored in the Migaku evidence knowledge base.
• Current evidence mix: 1 systematic review, 1 randomized trial.
• Claims should be interpreted with the source type, study design, population, and publication date in mind.
• This article is educational and does not replace care from a qualified clinician.

Evidence Map

What The Sources Report

• These changes contribute to increased sarcopenia risk during and after the menopausal transition, with implications for physical function, frailty, and long-term musculoskeletal health. [Naddafha Siavash (2026); evidence level 1]
• In addition, creatine may exert direct anabolic or anticatabolic effects on muscle cells and influence bone via increased muscle pulling forces or direct cell signaling in osteoblasts. [Naddafha Siavash (2026); evidence level 1]
• Motor symptoms produce profound functional limitations, stemming from muscle weakness that triggers atrophy, impaired balance, among other symptoms, all culminating in reduced daily physical activity that perpetuates sarcopenia and functional decline, all worsened by hospitalization. [Pizarro Eduard Bargay (2026); evidence level 2]
• Despite recent advances in acute care, post-stroke interventions remain suboptimal, especially those targeting physical and functional recovery. [Pizarro Eduard Bargay (2026); evidence level 2]

How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

Practical Interpretation

There is at least one systematic-review style source in the current set, so it deserves more weight than single-study evidence. There is trial evidence in the current set, but population and intervention details still matter. For creatine cognition randomized trial, the next editorial step is to add more targeted sources and separate strong findings from early or indirect evidence.

Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

References

• Naddafha Siavash (2026). Creatine monohydrate for lean mass, strength, and bone density in postmenopausal women: a systematic review and meta-analysis. DOI: 10.1080/15502783.2026.2668435. PMCID: PMC13182165. PMID: 42141930. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13182165/
• Pizarro Eduard Bargay (2026). ABSTRACT NUMBER: ESOC2026OT29 EFFECT OF CREATINE MONOHYDRATE SUPPLEMENTATION ON RECOVERY AFTER ISCHEMIC STROKE: THE SUCRE CLINICAL TRIAL. DOI: 10.1093/esj/aakag023.2014. PMCID: PMC13145170. License: https://creativecommons.org/licenses/by-nc/4.0/ https://creativecommons.org/licenses/by-nc/4.0/ This is an Open Acces.... https://pmc.ncbi.nlm.nih.gov/articles/PMC13145170/

Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.